David Naylor, MD
Family Medicine · Conway, ARNPI 1730166844
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 1,303 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,303 payments — averaging $12.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$2K
- GSK$1K
- AstraZeneca$1K
- Lilly USA, LLC$1K
- Pfizer$986
- plus $8K from 52 others
Across 3 payments — averaging $269.03 each. An ownership or investment interest held by the physician or an immediate family member.
- Sitesaver Inc.$807
What the payments were for
- Food & beverage$16,48299%
- Education$1901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,672 in reported general payments places this provider in the 95th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 206 | $203,303 |
| EliquisApixaban | 494 | $189,258 |
| JardianceEmpagliflozin | 257 | $143,951 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 22 | $135,454 |
| FarxigaDapagliflozin Propanediol | 163 | $99,281 |
| MounjaroTirzepatide | 92 | $97,312 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 117 | $80,180 |
| TrulicityDulaglutide | 67 | $72,005 |
| XareltoRivaroxaban | 94 | $46,490 |
| JanuviaSitagliptin Phosphate | 79 | $40,999 |
| GemtesaVibegron | 117 | $31,176 |
| LinzessLinaclotide | 45 | $26,513 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $24,865 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 72 | $22,468 |
| MyrbetriqMirabegron | 73 | $21,499 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,836 | $203,303206 claims |
| PfizerEliquis | $986 | $189,258494 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,160 | $169,317159 claims |
| Boehringer IngelheimJardiance, Tradjenta | $280 | $155,922281 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $104 | $135,45422 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,414 | $107,994176 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,467 | $105,936187 claims |
| AbbVieLinzess, Ubrelvy, Restasis | $2,036 | $50,70977 claims |
| MerckJanuvia, Belsomra | $210 | $47,392102 claims |
| Johnson & JohnsonXarelto | $457 | $46,49094 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $77 | $31,176117 claims |
| Astellas Pharma US IncMyrbetriq | $623 | $21,49973 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Conway
- Thad HardinConway$18K
- Lander SmithConway$16K
- Joe CumminsConway$15K
- John DicksonConway$15K
- Michael CarsonConway$14K
- Randal BowlinConway$11K
- Glenn GibbonsFort Smith$179K
- Hetal PatelParagould$147K
- David GersonSherwood$119K
- Scott MusickBentonville$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.